OnKure Therapeutics Reports $17.8 Million Q3 Loss
The Boulder biotech reported higher research spending and launched a vascular anomalies patient registry as it advances two drug candidates.
Updated on Nov. 4, 2026 in Biotech
OnKure Therapeutics reported a third quarter 2026 net loss of $17.8 million, or $0.36 per share, with cash, cash equivalents, and marketable securities of $163.3 million as of September 30, 2026. The company also initiated PANORAMA, a large-scale, multiregional, longitudinal observational registry of people living with vascular anomalies.
Why it matters
The results show research and development spending rising year over year as OnKure moves its OKI-355 and OKI-345 candidates toward regulatory filings. The PANORAMA registry is designed to build data on the natural course of vascular anomalies and on links between genetic variants and clinical characteristics.
The figures come from OnKure's third quarter 2026 financial filing, which shows R&D spending of $15.1 million, up from $11.9 million a year earlier, and a net loss of $17.8 million, or $0.36 per share, compared with $14.7 million, or $1.09 per share, in Q3 2025. Whether the pipeline produces clinical results that justify this spending remains unknown, since the filing does not report efficacy or safety data.
The players
OnKure Therapeutics
A clinical-stage biotechnology company headquartered in Boulder, Colorado, developing targeted oncology and vascular anomaly therapies.
The details
OnKure ended the quarter with $163.3 million in cash, cash equivalents, and marketable securities. The company said it plans to submit IND applications to the FDA for OKI-355 and OKI-345 in the first half of 2027. PANORAMA will offer genotyping to all participants and will support retrospective and prospective analyses of disease course and treatment patterns.
Timeline
March 2026: OKI-355 was announced to lead the vascular anomalies pipeline, and OKI-345 was selected for the breast cancer program.
September 30, 2026: Quarter ended with $163.3 million in cash and marketable securities.
November 4, 2026: Third quarter 2026 results were reported.
First half of 2027: OnKure plans to submit IND applications for OKI-355 and OKI-345.
2029: OnKure's cash is expected to provide runway into this year.
Big Picture
OnKure's OKI-355 is built on the finding that PIK3CA mutations drive a range of vascular malformations, the same genetic driver that has defined the PIK3CA-related overgrowth spectrum as a research area. The company's design to selectively inhibit mutant PI3Kα while sparing wildtype PI3Kα places it within that effort to treat the disease without broad suppression of normal signaling.
For patients living with vascular anomalies, the PANORAMA registry offers a route to enroll in observational research and receive genotyping of their condition. The registry does not itself change treatment access, which will depend on whether OKI-355 advances through clinical trials and regulatory review.
The takeaway
Patients and families tracking vascular anomaly treatments should watch for the planned 2027 IND filings and any registry enrollment details that follow. Investors and observers can track the company's cash runway into 2029 against its clinical milestones.
What happens next
OnKure plans to submit IND applications to the FDA for OKI-355 and OKI-345 in the first half of 2027.
Further reading
For more on the research field behind this company's pipeline, see Biotech coverage on Wisevoter.
Source note: This article includes information reported by The Manila times.
